At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 385 enrolled

Drug / intervention

Ipilimumab +4 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02060188

NCT02060188Phase 2Completed

Compare CT.gov

A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite Instability High (MSI-H) and Non-MSI-H Colon Cancer

Bristol-Myers Squibb·interventional·Posted Feb 11, 2014·Updated Nov 6, 2025

In Brief

A Phase 2 clinical trial evaluating Ipilimumab, Nivolumab, and 3 other interventions for Microsatellite Unstable Colorectal Cancer and 3 related conditions. Completed, enrolled 385 participants across 32 sites in 8 countries.

Detailed Summary

The purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their tumors.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMicrosatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer

CountriesAustralia, Belgium, Canada, France, Ireland, Italy, Spain, United States

Collaborators--

Timeline

Phase 2CompletedFinished

2014201520162017201820192020202120222023202420252026

First PostedFeb 2014

Enrollment StartMar 2014

Primary CompletionOct 2024

TodayJul 2026

First PostedFeb 11, 2014

Enrollment StartMar 12, 2014

Primary CompletionOct 22, 2024

TodayJul 2, 2026

Enrollment to primary: 10.6 yearsPosted 12.4 years ago